We treat chronic disease caused by microbiome dysbiosis. Our first indication affects 1/3 US population and presents a $16B annual market opportunity. Beyond that, we have disrupted drug discovery with a shorter timeline to market, faster investment return and relatively small up front investment. With our Lightning Rapid Carbohydrate Drug Discovery Platform, we have a pipeline of novel MIMOs targeting a range of upper and lower GI conditions.